Prevalence and clinical factors associated with gout in patients with diabetes and prediabetes.
Qiliang Liu,G. Gamble,K. Pickering,Sara Morton,N. Dalbeth
DOI: https://doi.org/10.1093/rheumatology/ker384
2012-04-01
Rheumatology
Abstract:SIR, The relationship between gout and diabetes is complex. Patients with gout have a high prevalence of type 2 diabetes [1]. Gout is also a risk factor for developing type 2 diabetes [2]. However, patients with diabetes have a lower risk of developing gout [3]. Although several studies have examined the clinical associations of diabetes in patients with gout, the prevalence and clinical associations of gout in patients with diabetes are not well documented. The aim of this study was to examine the prevalence of gout and the clinical factors associated with gout in a large community-based group of patients with diabetes. We analysed data from 18 358 patients with diabetes, impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) from the Diabetes Care Support Service (DCSS) register collected by specialist nurses between May 2007 and November 2010. The DCSS register contains annually collected clinical information for all patients with diabetes and IFG/IGT attending participating primary health-care clinics within Auckland, New Zealand [4]. This study was approved by the Northern X Regional Ethics Committee. Diagnosis of diabetes mellitus, IFG and IGT were defined according to the World Health Organization criteria [5]. The presence of gout was determined by physician diagnosis as recorded in clinical notes. Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease formula [6]. Statistical analysis and modelling were performed using SAS 9.2 (SAS Institute, Cary, NC, USA) and GraphPad Prism 5.02 (GraphPad Software, La Jolla, CA, USA). Prevalence values were directly standardized to Segi’s world population with 95% confidence intervals determined using www.openepi.com (accessed 17 December 2010). Multivariate logistic regression models were used to determine estimates for independent predictive contributions of each variable for each group. All P-values are two-sided, with P< 0.05 considered statistically significant. There were 733 patients with type 1 diabetes, 14 066 with type 2 diabetes and 3559 with IFG and/or IGT (IFG/ IGT). Mean (S.D.) age was 61 (14) years, diabetes disease duration 8.6 (7.8) years, BMI 32.4 (7.5) kg/m and haemoglobin A1c (HbA1c) 7.4 (1.6)%. There were 9473 (52.6%) men; 9515 (51.8%) were European. In the entire study group, there were 2778/18 358 (15.1%) patients with gout. The direct ageand sex-standardized prevalence (95% CI) of gout was 1.2% (0.5%, 1.9%) in patients with type 1 diabetes, 16.0% (15.4%, 16.5%) in type 2 diabetes and 14.2% (13.1%, 15.4%) in IFG/IGT (P< 0.0001 for type 1 vs both the other groups). Gout affected >20% of men with type 2 diabetes or IFG/IGT. Ethnicity-specific prevalence rates of gout varied considerably in patients with type 2 diabetes; ageand sex-adjusted prevalence (95% CI) was 5.0% (3.7%, 6.4%) in Indian, 12.5% (11.6%, 13.3%) in European and 28.5% (26.8%, 30.3%) in Māori. No clinical factors were independently associated with gout in patients with type 1 diabetes (data not shown). The following clinical factors were independently associated with a diagnosis of gout in patients with type 2 diabetes: age, male sex, Māori or Pacific ethnicity, lower eGFR, BMI, lower HbA1c, higher triglycerides, diuretic use and non-use of insulin and metformin (Table 1). In patients with IFG/IGT, the clinical factors independently associated with a diagnosis of gout were male sex, Māori or Pacific ethnicity, and lower eGFR (Table 1). This large community-based study has identified a high prevalence of gout in patients with type 2 diabetes and IFG/IGT, affecting one in five men. In contrast, the prevalence of gout in patients with type 1 diabetes was considerably lower. The prevalence of gout in patients with type 2 diabetes and IFG/IGT is high compared with the estimated 2009 national prevalence of gout in New Zealand of 2.7% [7]. Risk factors for gout in the general population such as age, male sex and renal impairment [1] were also associated with gout in this study of patients with type 2 diabetes. In addition, we have identified several diabetesspecific factors including low HbA1c and lack of hypoglycaemic medication that are associated with gout in this population. These findings are consistent with previous research that has demonstrated an inverse relationship between serum urate and HbA1c in the general population, particularly in men [8]. We acknowledge the potential limitations of our study. The cross-sectional design does not allow analysis of the direction of the relationships between gout and diabetes. The New Zealand setting may limit the international applicability due to high rates of gout in the indigenous Māori population [9]. However, the regression analyses identified a number of clinical factors associated with gout, independent of ethnicity. Although misclassification of gout may have occurred, physician diagnosis is standard in large epidemiological studies of gout [1]. Gout may have implications for diabetes management: active arthritis restricts exercise, gout may provide additional complexity to dietary management, medications for acute gout may contribute to diabetes complications and severe gout may lead to more complex foot disease. Gout